Non-Infectious Macular Edema Treatment Market Is Projected To Expand At 6.9% CAGR To US$ 29.6 Billion By 2034 | Fact.MR Report

(MENAFN- GlobeNewsWire - Nasdaq) The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market research report.

Rockville, MD, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The global non-infectious macular edema treatment market is anticipated to secure a valuation of US$ 15,121.9 million in 2024. The global market is forecast to increase at a 6.9% CAGR and reach a market value of US$ 29,567.8 million by the end of 2034.According to Fact MR, a provider of market research and competitive intelligence, the global non-infectious macular edema treatment market is rapidly growing and is expected to continue its growth trajectory in the coming years.

Advances in biologics and gene therapies for ocular diseases may open up new avenues for treating non-infectious macular edema. The innovative approaches can offer targeted and long-lasting therapeutic effects. Advancements in regenerative medicine, including stem cell therapy and tissue engineering, hold promise for the treatment of ocular diseases. Research in this area may lead to innovative approaches for non-infectious macular edema.

Integration of artificial intelligence and machine learning algorithms in diagnostic processes can enhance the accuracy and efficiency of diagnosing non-infectious macular edema, leading to timely interventions and improved patient outcomes. Collaborative efforts and global health initiatives focused on preventing blindness and treating eye diseases can contribute to the growth of the non-infectious macular edema treatment Market by increasing awareness and accessibility to treatments.

Research into combination therapies involving multiple modes of action may lead to more effective treatment strategies for non-infectious macular edema, addressing different aspects of the disease pathology simultaneously. Increased emphasis on patient education programs can enhance awareness about the importance of regular eye check-ups, early symptom recognition, and adherence to prescribed treatments, fostering a proactive approach to managing non-infectious macular edema.

For More Insights into the Market, Request a Sample of this Report:

Key Takeaways from the Market Study

• In 2024, the global non-infectious macular edema treatment market is estimated to have a global market size of US$ 215,121.9 million .
• The diabetic ME segment is expected to dominate the market, with a market share of 52.6% in 2034.
• The anti-VEGF category is expected to hold a market share of 67.7% in 2034.
• Brazil is predicted to acquire a 58.0% of the global market share in 2024.
• Latin America is expected to account for a CAGR of 7.0% by 2034.

“Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can foster the development and commercialization of new treatments for non-infectious macular edema,” says a Fact.MR analyst.

Leading Players Driving Innovation in the Non-Infectious Macular Edema Treatment Market:

Allergan, Plc.; Amgen, Inc.; Pfizer, Inc.; Novartis AG; F. Hoffman - La Roche Ltd.; AbbVie Inc.; Bayer AG; Valeant Pharmaceuticals Inc.; Alimera Sciences Inc.; Clearside Biomedical, Inc.

Competitive Landscape:

The non-infectious macular edema treatment market is shaped by pricing, distribution channels, customer service, and regulatory compliance to gain a competitive edge. Adapting to market dynamics and staying abreast of technological advancements are essential for sustained success in this dynamic industry.

Company Portfolio:

• Pfizer Inc.: It is a multinational pharmaceutical company with a broad portfolio covering various therapeutic areas. Pfizer has a strong presence in the development and marketing of prescription medicines. Pfizer has products related to eye care, including treatments for conditions such as macular edema.
• Novartis AG: It is a Swiss multinational pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of healthcare products, including pharmaceuticals and eye care. Novartis has been active in the field of ophthalmology, and its portfolio may include treatments for conditions like non-infectious macular edema.

Non-Infectious Macular Edema Treatment Industry News:

• Allergan Plc is a global pharmaceutical company known for its focus on aesthetics, eye care, central nervous system, and gastroenterology. Allergan has been a major player in the ophthalmology field. Allergan has been involved in the development and marketing of pharmaceuticals, including treatments for eye conditions. One of its notable products for non-infectious macular edema is Ozurdex (dexamethasone intravitreal implant), which is an implantable corticosteroid for the treatment of various retinal conditions, including macular edema.
• Amgen Inc. is a biotechnology company known for its focus on developing and manufacturing innovative biologic medicines. Amgen's portfolio includes products related to eye care.

Get Customization on this Report for Specific Research Solutions-

More Valuable Insights on Offer

The study reveals essential insights based on non-infectious macular edema treatment market analysis by drug type (anti-VEGF, corticosteroids, immunosuppressant, biologics, others), by route of administration (oral, parental, topica), by indication (non-infectious uveitic ME, diabetic ME, retinal vein occlusion ME), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and by region (North America, Latin America, Europe, East Asia, South Asia and Oceania, and Middle East & Africa).

Explore More Related Studies Published by Fact.MR Research:

The global fast melt tablet market is estimated to reach a valuation of US$ 16.9 billion in 2024 and further expand at a CAGR of 8.1% to achieve a size of US$ 36.68 billion by 2034-end.

The global shower chair market is estimated to reach US$ 5.14 billion and is forecasted to expand at a CAGR of 9% to reach US$ 12.21 billion by 2034.

Expanding at a CAGR of 16.3%, the global home DNA testing market is projected to increase from a valuation of US$ 4.62 billion in 2024 to US$ 20.96 billion by 2034.

Worldwide revenue from the global particle-enhanced turbidimetric immunoassay market is estimated at US$ 2.03 billion in 2024. The market is further projected to increase at a CAGR of 9.6% to touch a value of US$ 5.05 billion by 2034.

Worldwide revenue from the in vitro diagnostics test kits market is estimated to stand at US$ 12.35 billion in 2024 and is evaluated to increase at a CAGR of 6.4% to reach US$ 22.93 billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: ...
Follow Us: LinkedIn | Twitter | Blog

MENAFN03022025004107003653ID1109161418